[{"orgOrder":0,"company":"CDR Life","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"CDR Life","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CDR Life \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"CDR Life \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"CDR Life","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"CDR202","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"CDR Life","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CDR Life \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"CDR Life \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Arctos Medical","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Arctos Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal","sponsorNew":"Arctos Medical \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Arctos Medical \/ Novartis Pharmaceuticals Corporation"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Under the collaboration, the partners will advance CDR-Life’s preclinical antibody fragment-based therapeutic including CDR202, targeting a key pathway in geographic atrophy (GA).

                          Product Name : CDR202

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          February 08, 2023

                          Lead Product(s) : CDR202

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : Boehringer Ingelheim GmbH

                          Deal Size : $487.7 million

                          Deal Type : Collaboration

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The acquisition underscores the Novartis commitment to finding treatments for patients with vision loss and the potential of Optogenetics-based AAV gene therapy as the basis of successful therapeutics.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          September 21, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : Novartis Pharmaceuticals Corporation

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Together, with Boehringer Ingelheim’s expertise in the therapeutic development of biologics and CDR-Life’s strong know-how in antibody engineering, the two companies will progress CDR-Life’s preclinical candidate, with the aim to preserve sight for...

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          May 13, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : Boehringer Ingelheim GmbH

                          Deal Size : $494.0 million

                          Deal Type : Licensing Agreement

                          blank